HOCENA (Antroquinonol)
HOCENA (Antroquinonol)

新冠肺炎新藥雙重的成就:國鼎生技新藥臨床獲得美國DMC 數據資料安全委員會回應正向成果以及授權四個國家。
Covid-19 Drug Duo Achievements: GoldenBiotech’s New Drug Antroquinonol (HOCENA) Trial Receives Positive Response from DMC Review and Licenses for 4 Countries

LEADING IN MEDICAL BREAKTHROUGHS
LEADING IN MEDICAL BREAKTHROUGHS

國鼎生技開發新冠肺炎(Covid-19)新藥Antroquinonol (Hocena) / (GHCovid-2-001) 之國際授權市場,已啟動全球國際授權計畫。

Congratulation!
Congratulation!

國鼎生技新冠肺炎新藥授權首家授權韓國BNC Korea Co. Ltd.公司
GoldenBiotech Signs Licensing Agreement with BNC Korea Co. Ltd for Covid-19 Drug Cooperation.

News
Breakthrough in AML Treatment: GoldenBiotech Reports New Drug Trial of Antroquinonol -Outperforms Listing Drugs in Relapsed Acute Myeloid Leukemia TAIPEI, Nov.26, 2020- Golden Biotechnology Corp.(GoldenBiotech,...
Read More "News"
R&D Pipeline
We believe, expect and pioneer… Based on our ultimate spirit, GBC develops new drug candidates through our solid footstone and promotes health by promising and...
Read More "R&D Pipeline"
PHARMACEUTICAL
BREAKTHROUGHS FOR THE IDEAL MEDICINE Golden Biotechnology Corporation is a Taiwanese based leading pharmaceutical company which dedicates to discovering new compounds and developing innovative therapeutics...
Read More "PHARMACEUTICAL"

NEWS

Golden Biotechnology

Golden Biotechnology Corporation (GBC), founded by Mr. Sheng Yung, Liu in 2002, is an leading and innovative drug discovery and evidence-based healthy food supplement manufacturing company dedicated to enhancing lives by developing high quality products that prevent and treat diseases.

GBC’s main focus is on new drug R&D, IP right, pharmacology, toxicology and clinical studies. GBC also has successfully built up the screening platforms to identify bioactive compounds from traditional Chinese herbal medicine that includes more than 480 kinds of local plants, 1300 species of fungi, mushrooms and seaweeds.

Throughout 2002-2005, around 400 drug candidates were obtained from these screening platforms. Based on our own core chemical database, the ubiquinone-like structure of Antroquinonol® was actually discovered in 2006 during drug development. The pharmacology and toxicology of Antroquinonol® have been established along with the CMC (Chemistry, Manufacturing, and Controls) development and large-scale cGMP manufacturing of Antroquinonol®.